
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
Could intrathecally administered methotrexate be a viable treatment option for your patients with progressive forms of multiple sclerosis?
Could intrathecally administered methotrexate be a viable treatment option for your patients with progressive forms of multiple sclerosis?
Here to discuss the results of a study designed to test the feasibility of this therapeutic approach is neurologist Saud Sadiq. Dr Sadiq is Founder and Director of the
Dr Sadiq and his coauthors published their study in the
Intrathecal Methotrexate for Patients With MS?





